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Background. Human papillomavirus (HPV) vaccines are recommended for girls prior to sexual debut because
they are most effective if administered before girls acquire HPV. Little research has been done on HPV prevalence in
girls who report not having passed sexual debut in high HPV-prevalence countries.
Methods. Using attendance registers of randomly selected primary schools in the Mwanza region of Tanzania,
we enrolled girls aged 15–16 years who reported not having passed sexual debut. A face-to-face interview on sexual
behavior and intravaginal practices, and a nurse-assisted self-administered vaginal swab were performed. Swabs were
tested for 13 high-risk and 24 low-risk HPV genotypes.
Results. HPV was detected in 40/474 (8.4%; 95% conﬁdence interval [CI], 5.9–11.0) girls. Ten different high-risk
and 21 different low-risk genotypes were detected. High-risk genotypes were detected in 5.3% (95% CI, 3.5–7.8). In
multivariable analysis, only intravaginal cleansing (practiced by 20.9%) was associated with HPV detection (adjusted
odds ratio = 2.19, 95% CI, 1.09–4.39).
Conclusion. This cohort of adolescent Tanzanian girls had a high HPV prevalence prior to self-reported sexual
debut, and this was associated with intravaginal cleansing. This most likely reﬂects underreporting of sexual activity,
and it is possible that intravaginal cleansing is a marker for unreported sexual debut or nonpenetrative sexual behaviors.
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Cervical cancer is the most common form of cancer in
women in sub–Saharan Africa and the highest age-
standardized incidence of cervical cancer in the world
is found in East Africa at over 30.0 per 100 000 per-
son-years [1]. This is compared with approximately
15.0 per 100 000 women worldwide, and 6.0 per
100 000 in North America [1]. Almost all cases of
cervical cancer can be attributed to infection with 1 of
13 high-risk oncogenic genotypes of the human papil-
lomavirus (HPV) [2]. Although limited in number,
studies in women indicate that East Africa also has
one of the highest global prevalences of HPV infection
[3, 4]. Worldwide data consistently show that the prev-
alence of HPV is highest in younger women, most of
whom will clear the infection within 10 months [5].
The early peak of HPV prevalence by age is explained
by a rapid acquisition of HPV around the time of ﬁrst
sex in a previously unexposed, or immune-naïve, indi-
vidual [6, 7].
The 2 available HPV vaccines, Gardasil (MSD) and
Cervarix (GlaxoSmithKline Biologicals), cover the 2
most common cancer-causing HPV genotypes HPV-
16 and -18. Additionally, Gardasil covers HPV-6 and
-11, which, though low-risk for cervical cancer, are
common causes of genital warts. HPV vaccination is
most effective if administered prior to acquiring
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infection with these vaccine-related genotypes [8]. Data from
North America and Europe support the assumption that most
girls and women are HPV naive prior to ﬁrst sex and that HPV
is acquired quickly after sexual debut and with changes of sexual
partner [7, 9].However, there are no data on HPV prevalence in
young women prior to reported sexual debut from high HPV-
prevalence countries in sub–Saharan Africa, where sexual be-
havior, vaginal hygiene practices, and rates of underreporting
of sexual debut may differ. Such data are important because
they may identify modiﬁable risk factors for HPV infection,
and because any planned national vaccination campaign will
target young girls who are assumed to be HPV naive. Further,
the World Health Organization (WHO) has recommended vac-
cination catch-up campaigns in older girls if a signiﬁcant pro-
portion can be assumed to be naive to vaccine genotypes [10].
To address the gaps in knowledge, we present baseline cross-
sectional results from a cohort study in Tanzania that enrolled
adolescent girls who reported that they had not passed sexual
debut, and who were tested for vaginal HPV DNA. This study
is the ﬁrst to describe HPV prevalence in girls in sub–Saharan
Africa who report no previous sexual intercourse, and the asso-
ciations between reported sexual behaviors, vaginal practices,
and HPV infection.
METHODS
Cohort Enrolment
The cohort was enrolled between January and August 2012
from previously prepared attendance lists of randomly selected
government primary schools in 3 districts of the Mwanza Re-
gion in Tanzania. These lists, covering all primary schools in
the districts, had been drawn up in 2010 to prepare for a trial
of delivery methods for HPV vaccine [11]. The lists contained
the pupil’s name, date of birth, and which class they were en-
rolled in. Tracing information had also been collected on all
girls. We enrolled eligible girls who had attended 1 of the 82
schools not selected to receive the vaccine.
Eligibility criteria included being aged 15 or 16 years at en-
rolment, enrolled in class 6 in 2010 in 1 of the selected schools,
not pregnant (self-reported), planning to stay in the study area
or able to travel to appointments, self-reporting never having
had vaginal sex, and being willing to self-administer vaginal
swabs. A subsample of 26 of the 82 schools were randomly se-
lected and, in order to prevent stigmatization of girls who re-
ported sex, at each of these 26 schools the ﬁrst girl who
reported ever having had sex was enrolled. An additional eligi-
bility requirement for these girls was having passed sexual debut
within the past 12 months.
Ethical Issues
The London School of Hygiene and Tropical Medicine Ethics
Committee and the Medical Research Coordinating Committee,
Tanzania, approved the study protocol. Because all potential
participants were considered minors in Tanzania (under 18
years old), written informed consent was required from a par-
ent/guardian with subsequent participant informed assent.
Consent for enrolment was taken before any assessment of pre-
vious sexual debut. The consent procedure involved separate
face-to-face explanations of the study to parents and daughters
by a study nurse, provision of written information, and time to
ask questions. Individuals unable to read were consented in the
presence of an independent witness who provided an additional
signature. Individuals unable to write provided a thumbprint.
Parents/guardians were compensated for their time with
Tsh5,000 (approximately $3), and participants were provided
with a toothbrush and toothpaste.
Study Procedures
After enrolment, girls had a face-to-face interview with a female
study nurse. Interviews were carried out in private at the partic-
ipant’s home, school, or local health center, depending on par-
ticipant preference. Interviews were carried out in Swahili using
a structured paper questionnaire, which had been translated
and back-translated from English. Questions covered demo-
graphic and socioeconomic details, menstrual and vaginal hy-
giene practices, nonpenetrative sexual behaviors, and details
of previous penetrative-sex frequency and partners. Interviews
included colloquial terms for sexual behaviors that had been
collected during focus group discussions with similar-aged
girls. One self-administered vaginal Dacron swab was obtained
after instructions from a study nurse, who remained in the
room and provided verbal and positional hand guidance if nec-
essary. Girls are being followed every 3 months for 18 months.
We report results from the enrolment visit.
HPV Detection and Genotyping
Immediately after collection, swabs were stored dry in cryotubes
and placed into cold boxes with ice packs. They were submitted
daily to the reference laboratory in Mwanza and stored at−20°C
until they were shipped to the Catalan Institute of Oncology,
Barcelona, Spain. HPV detection and genotyping were per-
formed using the Linear Array HPV genotyping assay (Roche,
CA) which detects 37 HPV genotypes (HPV-6, -11, -16, -18,
-26, -31, -33, -35, -39, -40, -42, -45, -51, -52, -53, -54, -55,
-56, -58, -59, -61, -62, -64, -66, -67, -68, -69, -70, -71, -72,
-73, -81, -82, -83, -84, IS39, and CP6108). For this study, 13
HPV genotypes, HPV-16, -18, -31, -33, -35, -39, -45, -51, -52,
-56, -58, -59, and -68, were classiﬁed high-risk [2]. Other geno-
types were considered low-risk.
Brieﬂy, DNA was extracted from the specimens by silica-
gel-based methods (AmpliLute Liquid Media Extraction kit,
Roche). Extracted material was ampliﬁed with the PGMY
PCR system, and the generated amplicons were detected and
typed by reverse-line blot reaction (Linear Array HPV
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Detection Kit and Genotyping Test, Roche). Polymerase chain
reaction in this assay is based on a multiplex system, including
human β-globin ampliﬁcation primers. This provides an inter-
nal quality control for sample material. Specimens consistently
negative for β-globin ampliﬁcation were excluded because it was
assumed that vaginal sampling was unsuccessful. All protocols
were performed according to manufacturer’s instructions: each
step was performed in separate rooms and negative controls
were used.
Data Management and Statistical Methods
Questionnaire data were double-entered into OpenClinica LLC
(Akaza Research, Waltham, MA), and analyzed using STATA
V12.0 (StataCorp LP, College Station, TX). Baseline cohort
characteristics were examined, and the prevalence of any HPV
infection and prevalence of individual HPV genotypes were cal-
culated. Household wealth was estimated using a score based on
the number of possessions owned by the head of the household
in which the participant currently resided. Median age of
menarche in the cohort was calculated using Kaplan–Meier sur-
vival methods to account for those who had not reached
menarche.
Factors associated with prevalent HPV infection (treated as a
binary outcome for any HPV genotype vs none) were identiﬁed
using logistic regression models. Age was considered an a priori
potential confounder, and factors reaching P < .1 after adjustment
for age were included in a multivariable model. Vaginal cleansing
was investigated as a binary term for ever having cleansed, and as
frequency of cleansing categorized as never, ≤2, and ≥3 times per
day. All P values are from likelihood ratio tests.
RESULTS
Of 1555 potentially eligible girls on the original school atten-
dance lists, 1177 (76.5%) were located. From these, 801
(68.1%) were conﬁrmed to be the appropriate age, and 628
(78.4%) consented to be screened for enrollment (Figure 1).
Of those screened, 503 (80.1%) were eligible, selected, and
Figure 1. Flow diagram of cohort enrollment. *146 (84.4%) were parents and 27 (15.6%) were girls.
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enrolled, of whom 481 (95.6%) reported not having had sex.
Those not enrolled either reported having had sex and were
not randomly selected for inclusion (N = 102, 16.2%), or said
they were planning to move out of the study area (N = 23,
3.7%). β-globin was detected in 495 (98.8%) of specimens. We
excluded 6 participants from the analysis who provided β-
globin–negative vaginal swabs, and 1 who did not provide a
swab. We present HPV prevalence and associated factors
from the remaining 474 girls who reported never having had
sex, and the HPV prevalence in girls who reported having
had sex within the past year.
Cohort Description
Of the 474 participants who reported never having had sex, 225
were aged 15 (47.5%) and the remainder (52.5%) were 16 years
old (Table 1). Only 11 (2.3%) reported ever having kissed, and
34 (7.2%) reported allowing a boy to touch their breasts. One
girl reported touching a boy’s penis, and another reported al-
lowing a boy to touch her vagina. None reported oral or anal
sex. The majority had passed menarche (N = 376, 79.3%). Me-
dian age of menarche in the cohort was 15 years (interquartile
range, 14–15). One-ﬁfth (N = 99, 20.9%) reported ever having
cleansed inside their vagina; 78.8% (N = 78) using ﬁngers and
the remainder using a cloth (Table 2). Approximately half
(53.5%) of those reporting cleansing used soap and water; the
other half used water alone. One participant reported inserting
a substance, tobacco powder, into her vagina.
HPV DNA Prevalence
HPV DNA was detected from vaginal swabs in 40 of 474 girls
who reported not having passed sexual debut, giving a preva-
lence of 8.4% (95% conﬁdence interval [CI], 5.9–11.0). In
total, 24 (5.1%, 95% CI, 3.1–7.0) girls had a high-risk HPV ge-
notype. Multiple genotype infections were detected in 20 (4.2%,
95% CI, 2.4–6.0) girls, comprising 50.0% of those with HPV
DNA. The 2 most commonly detected genotypes were HPV-
42 and HPV-58, with a prevalence of 1.9% (N = 9) and 1.1%
(N = 5), respectively (Figure 2). The prevalence of infection
with any of the vaccine genotypes HPV-6, -11, -16, or -18
was 1.6% (95% CI, .5–2.7).
A total of 22 eligible girls who reported having passed sexual
debut within the last year were enrolled from 26 randomly select-
ed schools. HPV DNA was detected in 7 (31.8%, 95% CI, 10.7–
53.0) of these 22 girls, signiﬁcantly higher than in those who
reported never having had sex (P < .01), and high-risk HPV was
detected in 22.7% (95% CI, 3.7–41.7, N = 7). Though the numbers
involved were small, their demographic proﬁle was similar to that
of girls who reported no previous sex (data not shown).
Associations With HPV
In univariable analyses of 474 girls who reported never having
had sex, there was weak evidence that being age 16 years was
associated with HPV detection (odds ratio, 1.76, 95% CI, .89–
3.47; P = .10). Only the reporting of ever having practiced intra-
vaginal cleansing was associated with HPV DNA detection in
univariable analysis, and this persisted after adjustment for
age (adjusted OR [aOR], 2.19, 95% CI, 1.09–4.39; P = .03)
(Table 1). Furthermore, there was strong evidence of a dose-
response relationship between cleansing frequency and HPV
DNA detection (per unit increase in cleansing frequency cate-
gory after adjustment for age, aOR, 1.54, 95% CI, 1.17–2.03;
P = .002). However, among girls who reported cleansing, there
was no evidence of an association of HPV detection with meth-
od (ﬁngers vs cloth), or substance used (water alone vs soap)
(Table 2).
DISCUSSION
In the ﬁrst study to examine the epidemiology of HPV in girls
from sub–Saharan Africa who self-reported never having en-
gaged in vaginal sex, the prevalence of HPV was surprisingly
high (8.4%) based on the testing of self-administered vaginal
swabs. This is higher than in 2 previous studies among
women who reported no previous sex: 1 study of 130 Swedish
women aged 10–25 years reported a prevalence of 1.5%, and 1
longitudinal study of American women aged 18–20 years re-
ported that 1.7% of specimens were found to have HPV DNA
[7, 9]. A further 3 small studies in Sweden, Denmark, and Aus-
tralia found no HPV DNA in cervical or vaginal specimens
from 15, 30, and 55 women, respectively, aged between 13
and 41 years, who reported no previous sex [12–14].
Previous studies have conﬁrmed vaginal sex as the predomi-
nant method for acquisition of cervical HPV infection in
women, as demonstrated by rapid HPV acquisition after report-
ed sexual debut, and a signiﬁcant increase in the risk of HPV
infection with increased number of partners and with high-
risk partners [13, 15]. Lack of disclosure of previous sex is,
therefore, the most likely explanation for the relatively high
HPV prevalence observed in our study. Previous research in ad-
olescents in different world regions consistently illustrates un-
derreporting of sexual behaviors [16, 17], and studies
conducted in the same geographical area of Tanzania as this
study have demonstrated underreporting of sex in girls of sim-
ilar ages, and in older, sexually active women [16, 18]. In young
females in this region of Tanzania in which the median age of
reported sexual debut is 16 [19], potential consequences of dis-
closure of sex under the age of 16 include expulsion from
school, physical punishment, and social exclusion [20]. Howev-
er, irrespective of reporting errors, ﬁnding HPV in specimens
collected from girls who report no previous vaginal sex remains
important. Vaccine efﬁcacy is highest in those who have not
previously been exposed to the vaccine-related HPV genotypes,
and age of vaccination is based on the assumption that girls are
HPV negative prior to self-reported sexual debut [21]. Our data
840 • JID 2014:210 (15 September) • Houlihan et al
Table 1. Analysis of Factors Associated With Detection of HPV in Adolescent Girls Who Reported Never Having Had Sex (n = 474)
Characteristic No. (%)
HPV Positive
No. (%)
Age-Adjusted Analysis
Ever Inserted Ever Inserted
OR (95% CI)a P Valueb aOR (95% CI)c P Valueb
Overall 474 40 (8.4)
Sociodemographic
Age (years)
15 225 (47.5) 14 (6.2) 1 .10 1 .10
16 249 (52.5) 26 (10.4) 1.76 (.89–3.47) 1.74 (.88–3.43)
Current residence
Urban 233 (49.2) 16 (6.9) 1 .13 1 .29
Rural 241 (50.8) 24 (10.0) 1.47 (.76–2.84) 1.43 (.74–2.79)
Lives with
1 or both parents 359 (75.7) 31 (8.6) 1 .23 1 .63
Other relatives or friends 115 (24.3) 9 (7.8) 0.84 (.39–1.84) 0.83 (.38–1.81)
Husband 0 . . . . . .
Composite measure of household wealth
High 113 (23.8) 11 (8.3) 1 .40 1 .91
Medium 228 (48.1) 18 (7.9) 0.84 (.38–1.85) 0.78 (.35–1.73)
Low 133 (28.1) 11 (9.7) 0.91 (.37–2.19) 0.87 (.36–2.11)
Current occupation
Schooling or vocational training 329 (50.4) 25 (7.6) 1 .15 1 .33
Working 6 (0.8) 0 . . . . . .
Not working, not schooling 139 (29.3) 15 (10.8) 1.44 (.73–2.82) 1.40 (.71–2.77)
Religion
Christian 417 (88.0) 35 (8.4) 1 .21 1 .30
Muslim 43 (9.1) 3 (7.0) 0.85 (.25–2.88) 0.76 (.22–2.63)
Other religion 8 (1.7) 2 (25.0) 3.28 (.63–17.06) 4.15 (.79–21.96)
None 6 (1.3) 0 . . . . . .
Alcohol, drugs, or cigarettes (ever)
No 473 (99.8) 40 (8.5) . . . . . . . . .
Yes 1 (0.2) 0 . . . . . .
Sexual Behavior
Kissed, ever
No 463 (97.5) 40 (8.6) . . . . . . . . . . . .
Yes 11 (2.3) 0
Breast touching, ever
No 440 (92.8) 38 (8.6) 1 .53 1 .63
Yes 34 (7.2) 2 (5.9) 0.62 (.11–2.72) 0.71 (.16–3.10)
Hand-genital contact with a boy, ever
No 472 (99.6) 40 (8.5) . . . . . . . . . . . .
Yes 2 (0.4) 0
Oral sex, ever
No 474 (100) 40 (8.4) . . . . . . . . . . . .
Yes 0 0 . . . . . .
Menstruation
Passed menarche
No 98 (20.7) 7 (7.1) 1 .24 1 .84
Yes 376 (79.3) 33 (8.8) 1.73 (.88–3.43) 1.09 (.46–2.58)
Sanitary item used during menstruationd
Cloth or paper 171 (36.1) 11 (6.4) 1 .33 1 .34
Underwear 77 (16.2) 8 (10.4) 1.67 (.64–4.33) 1.69 (.65–4.41)
Sanitary napkin 128 (27.0) 14 (11.0) 1.90 (.83–4.84) 1.78 (.77–4.13)
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reinforce WHO recommendations that vaccination should be
targeted at younger girls [10] and suggest that the vaccination
target age should be several years before the median age of
self-reported sexual debut in the population.
Alternative explanations for the presence of vaginal HPV
DNA in girls and women who report no previous sex include
mother-to-child transmission (MTCT) of HPV, nonpenetrative
sex practices, or transmission via fomites [22].MTCT is the pri-
mary mechanism for HPV acquisition in cases of respiratory
papillomatosis in children. However, in well-conducted pro-
spective studies, MTCT of genital HPV types was infrequent
and most often transient [23, 24].Transmission through nonpe-
netrative sex practices such as hand-genital or oro-genital
contact has been described in exclusively homosexual women
in the United States who report never having had sex with a
man (4/21 women, 19%) [25]. However, only 2 participants
in our sample reported these practices, and neither had detect-
able vaginal HPV DNA.
In the age-adjusted analysis in our study, disclosure of ever
having practiced intravaginal cleansing was associated with
more than doubled odds of prevalent HPV. Furthermore, a pos-
itive dose-response relationship was seen with increasing
frequency of vaginal cleansing. Commonly, women use intrava-
ginal practices (IVP) to manage menstruation, as part of their
sexual practice (altering vaginal lubrication or tightness), and
to improve genital hygiene. IVP includes both cleansing inside
the vagina with water, soap, or other products, and the insertion
of products into the vagina (eg, pulverized herbs) [26]. IVP is a
common practice in many parts of sub–Saharan Africa [27],
and has been reported in 96% of women working in bars and
guesthouses in Tanzania [26]. In that population, many
women reported initiating IVP at the time of menarche or
when they were given instruction about sex or marriage [28],
and in our study, 20.9% of girls reported intravaginal cleansing.
IVP has been associated with increased risk of HIV acquisition
in sex workers in Kenya, and with a doubled risk of acquisition
of a new sexually transmitted infection (STI) in a prospective
study of adolescent girls in the United States [29, 30].With spe-
ciﬁc relevance to HPV, a cross-sectional study of 312 adolescent
girls in the United States found that vaginal cleansing in the past
90 days was associated with a doubling of the odds of cervical
HPV infection [31].
HPV has been detected in ﬁngernail and ﬁngertip specimens
of young sexually active women in the United States, as well as
on toilet seats in several European airports, and on surfaces in a
sexual health clinic in the United Kingdom [32, 33]. HPV’s vi-
ability to cause infection of animal cells after desiccation has
Table 1 continued.
Characteristic No. (%)
HPV Positive
No. (%)
Age-Adjusted Analysis
Ever Inserted Ever Inserted
OR (95% CI)a P Valueb aOR (95% CI)c P Valueb
Intravaginal practices
Ever cleansed
No 375 (79.1) 26 (6.9) 1 .03 1 .03
Yes 99 (20.9) 14 (14.1) 2.19 (1.09–4.39) 2.19 (1.09–4.39)
Ever inserted
No 473 (99.8) 40 (8.5) . . . . . . . . . . . .
Yes 1 (0.2) 0 . . . . . .
Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; HPV, human papillomavirus.
a ORs adjusted for age as a priori confounder.
b P value from likelihood ratio test.
c ORs adjusted for age and ever cleansed.
d Of those passed menarche.
Table 2. Intravaginal Cleansing and HPV Prevalence
Characteristic No. (%)
HPV
Positive
No. (%)
aOR
(95% CI)a
P
Valueb
Frequency of cleansing
Never 375 (79.1) 26 (6.9) 1 .01
≤2 per day 61 (12.9) 5 (8.3) 1.21 (.44–3.28) P
trend=
.002
≥3 per day 38 (8.0) 9 (23.7) 4.03 (1.72–9.45)
Cleansed with
Water 46 (46.5) 5 (10.9) 1 .39
Soap +water 53 (53.5) 9 (17.0) 1.67 (.51–5.39)
Cleansed using:
Fingers 78 (78.8) 13 (16.7) 1 .13
Cloth 21 (21.2) 1 (4.7) 0.25 (.03–2.04)
Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; HPV, human
papillomavirus.
a Adjusted for age as a priori confounder.
b P value from likelihood ratio test.
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been demonstrated in a United Kingdom laboratory setting
[34]. In East Africa, HPV infection in women is highly prevalent
[3, 35, 36] and therefore an adolescent girl who performs intra-
vaginal cleansing may theoretically self-infect with HPV either
from her own external or extragenital sites, or from objects such
as cloth, taps, or water buckets contaminated from other house-
hold members. Acquisition of HPV from household members
may be direct, via the insertion of shared cloths, or indirect via
contaminated ﬁngers. A similar explanation has been postulated
for the presence of vaginal Trichomonas vaginalis in Zambian
girls aged 13–16 who reported no previous sexual contact
[37]. Intravaginal cleansing may additionally increase the risk
of HPV infection through vaginal mucosal abrasions, allowing
HPV to access target basal membrane cells, or through alter-
ation of the vaginal microbiome, which has been associated
with increased risk of other viral STIs, including HIV [38].
An important and likely explanation for the observed associ-
ation between intravaginal cleansing and HPV is that intravagi-
nal cleansing may be a marker of unreported sexual debut or
nonpenetrative sex behaviors. Girls may be more likely to
start vaginal cleansing after sexual debut because they believe
that this may prevent pregnancy or STIs, relieve STI-related
symptoms, or because they have been taught that this practice
is appropriate for sexually active women [27]. Increased fre-
quency of cleansing has been associated with higher number
of sex acts and/or partners [26], as has HPV acquisition [7],
which may explain the dose-response relationship between in-
travaginal cleansing and HPV infection seen in our study.
Multiple HPV-genotype infections were as common as single
genotype infections in this study, consistent with observations
in adolescent girls in previous studies in the United States
[31, 39]. More than half of the girls with HPV were found to
have a high-risk genotype, also consistent with the literature on
sexually active adolescent girls or young women in Denmark,
Canada, and Tanzania [13, 35, 40]. Of the 40 girls who had
HPV, only 6 (15.0%) had 1 of the 4 HPV genotypes included
the currently licensed vaccines, and only 4 (10.0%) had 1 or
both of the 2 high-risk genotypes in the vaccine.
Major strengths of this study include the interview method,
in which the questionnaire included local age-speciﬁc colloquial
terms for sexual practices, and was administered by trained
nurses experienced in adolescent sexual behavior research. In
addition, vaginal swabs were self-administered but collection
was directly observed by nurses. Self-administered vaginal
swabs in a previous local study (median age 17) demonstrated
collection of epithelial cells in 233/244 (95%) of swabs [41], and
99% of our specimens contained β-globin, indicating successful
sampling. Studies have shown a strong correlation for HPV de-
tection between clinician-collected and self-administered vagi-
nal swabs [42, 43]. Finally, the method used for HPV detection
and genotyping, Roche Linear Array, has been proven in large
studies to be highly sensitive [44, 45].
One of the limitations of this study is that the enrollment list
came from primary schools. Although primary school atten-
dance is a legal requirement in Tanzania, and has been reported
as 97% [46], it may be lower in rural populations and in upper-
primary-school years (from which this sample was drawn), and
may have affected the representativeness of the sample. Similar-
ly, the refusal rate was 22%, which may have also affected sam-
ple representativeness, and the small sample size resulted in
limited statistical power to detect associations. During screening
for study enrollment, a higher than expected proportion
Figure 2. Human papillomavirus (HPV) genotypes detected in girls reporting never having had sex (n = 474).
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(80.3%) reported no previous sex. This may reﬂect underreport-
ing, and could relate to parental involvement in consent proce-
dures. Biological markers would have allowed us to detect
previous sex and mitigated some of the bias from relying on
self-report. Unfortunately, currently available markers in vaginal
ﬂuids (Y-chromosome, semenogelin, prostate-speciﬁc antigen)
do not reliably detect previous sex that occurred over 14 days
prior to sample collection [47].A serological marker of sexual ex-
posure, such as herpes simplex virus type-2 (HSV-2) antibody
[48] was not measured because of budget constraints, concerns
that drawing a blood sample may have increased refusal rate,
and because HSV-2 is not a gold standard for the detection of
sexual debut [49]. Finally, self-administered vaginal swabs were
collected rather than physician-collected endocervical specimens.
The HPV genotypes detected therefore may not reﬂect cervical
HPV genotypes [50]. However, it has been argued that vulvo-
vaginal HPV infections may ascend to the cervix [7].
The proposed HPV vaccination program in Tanzania will
target girls in primary school class 4, where the median age is
10 years, and a catch-up campaign in older girls has not thus far
been proposed. This study provides useful evidence for policy-
makers in relation to the likely effectiveness of such a campaign.
Overall, 80.3% of 15–16 year old girls reported no previous sex,
99.2% of whom did not have infection with either of the 2 high-
risk HPV genotypes included in current HPV vaccines (HPV-
16/18). The WHO recommend including older girls in catch-up
campaigns if a signiﬁcant proportion of girls are naive to HPV
vaccine types [10]; our ﬁndings suggest that such a campaign in
older girls may be efﬁcacious in preventing infection with these
HPV types.
The data we present strongly link prevalent HPV infection
with reported intravaginal cleansing. Intravaginal cleansing
may be a marker for undisclosed sexual activity in our popula-
tion, but could alternatively be a novel mechanism for the non-
sexual transmission of HPV. If this is the case, the identiﬁcation
of this potentially modiﬁable risk factor would be highly rele-
vant for a country with one of the highest rates of cervical can-
cer in the world. Further research to conﬁrm and understand
the link between intravaginal cleansing and HPV is required
and is currently underway in Mwanza.
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